13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-07-30 Event 2026-07-23 SEC 0000059478-26-000072 →

ELI LILLY & Co Scribe Therapeutics, Inc. SCTX

Stake: 7.30% Shares: 1,388,161 CUSIP: 811033109 Class: Common stock, $0.001 par value per share

Item 4 — Purpose of Transaction

The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to acquire or dispose of Common Stock of the Issuer or any securities exercisable for or convertible into Common Stock of the Issuer, but the Reporting Person, consistent with its investment purpose, may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer. The Reporting Person's determination to make any such acquisitions or dispositions, in each such case, will depend upon a variety of factors, including, but not limited to, an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. In addition, in connection with the foregoing, the Reporting Person may engage in hedging or other transactions with respect to securities of the Issuer, including but not limited to, swaps and other derivative instruments. As part of its ongoing evaluation of its investment in the Issuer, the Reporting Person expects to engage in discussions with directors, officers, members of management and representatives of the Issuer, and may engage in discussions with stockholders, security holders or other interested parties, from time to time covering a range of topics concerning its investment and the Issuer, including operational, financial and strategic initiatives. Furthermore, without limitation, the Reporting Person may also evaluate and discuss other ideas, that if effected, may relate to, or result in, any other matter listed in Items 4(a)-(j) of Schedule 13D. To facilitate its consideration of such matters, the Reporting Person may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Person may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Person will likely take some or all of the foregoing steps at preliminary stages in its consideration of various possible courses of action before forming any intention to pursue any specific plan or proposal. Other than as described above, the Reporting Person reports that neither it nor, to its knowledge, any of the other persons listed on Schedule A attached to this Schedule 13D, currently has any specific plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Person may, at any time and from time to time, review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto.

Cross-References

Insider Activity (last 365d)
11 transactions
11 buys · 0 sales · 0 awards/exercises
Issuer Cluster
3 13D/G filings on this issuer
2 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-07-28 Aghazadeh Behzad director, 10%+ owner Buy 7,905 $18.25 $144K
2026-07-24 Aghazadeh Behzad director, 10%+ owner Buy 2,333,333 $15.00 $35.00M
2026-07-24 Aghazadeh Behzad director, 10%+ owner Buy 50,000 $22.31 $1.12M
2026-07-23 Lucas Svetlana officer Buy 3,000 $15.00 $45K
2026-07-23 Lucas Svetlana officer Award 109,426 $15.00 $1.64M
2026-07-23 Oakes Benjamin L. director, officer Award 264,784 $15.00 $3.97M
2026-07-23 Oakes Benjamin L. director, officer Award 429,599 $15.00 $6.44M
2026-07-23 GORDON CARL L director Award 14,725 $15.00 $221K
2026-07-23 Watson James Dean director Award 14,725 $15.00 $221K
2026-03-13 Lucas Svetlana officer Award 9,547 $19.13 $183K
2026-03-13 Oakes Benjamin L. director, officer Award 12,969 $19.13 $248K

Other 13D/G Filings on Scribe Therapeutics, Inc.

FiledFormFilerStakeShares
2026-07-30 SCHEDULE 13D Avoro Capital Advisors LLC 16.37% 2,598,973 view →
2026-07-29 SCHEDULE 13D ORBIMED ADVISORS LLC 7.20% 1,348,825 view →

Other Filings by ELI LILLY & Co

FiledFormIssuerStakeShares
2026-07-24 SCHEDULE 13G Ionetix Corp / DE / view →
2023-08-14 SC Sigilon Therapeutics, Inc. view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →